PureTech Health plc (PTCHF)
| Market Cap | 431.47M |
| Revenue (ttm) | 6.39M |
| Net Income (ttm) | 50.68M |
| Shares Out | n/a |
| EPS (ttm) | 0.20 |
| PE Ratio | 8.51 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,000 |
| Average Volume | 13,226 |
| Open | 1.700 |
| Previous Close | 1.680 |
| Day's Range | 1.680 - 1.700 |
| 52-Week Range | 1.270 - 2.200 |
| Beta | 0.82 |
| RSI | 46.02 |
| Earnings Date | Nov 28, 2025 |
About PureTech Health
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. The company also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; and delivers transformative medicines for patien... [Read more]
Financial Performance
Financial StatementsNews
PureTech Presents New Phase 2b Analyses Demonstrating Consistent Safety and Efficacy of Deupirfenidone in Older Patients with Idiopathic Pulmonary Fibrosis (IPF), a Historically Undertreated Group
BOSTON--(BUSINESS WIRE)--PureTech Presents New Phase 2b Analyses Demonstrating Consistent Safety and Efficacy of Deupirfenidone in Older Patients with IPF.
Pres. Trump's deal with Pfizer is pretty devastating to PBMs and insurance companies: John Lamattina
John Lamattina, PureTech Health senior partner and former Pfizer Global R&D president, joins 'Squawk Box' to discuss President Trump's deal with Pfizer, impact on drug prices, what the deal means for ...
PureTech Presents New Data from Phase 2b Open-Label Extension Study of Deupirfenidone (LYT-100), Further Supporting Strong and Durable Efficacy and Potential to Serve as New Standard of Care in IPF
BOSTON--(BUSINESS WIRE)--PureTech Presents New Data from Deupirfenidone Phase 2b Open-Label Extension, Further Supporting Potential to Serve as New Standard of Care in IPF.
What Makes PureTech Health (PRTC) a New Buy Stock
PureTech Health (PRTC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
PureTech Health (PRTC) Begins Phase 1 GlyphAgo Study
PureTech Health (PRTC) Begins Phase 1 GlyphAgo Study
PureTech Health plc (PRTC) Q2 2025 Earnings Conference Call Transcript
PureTech Health plc (NASDAQ:PRTC) Q2 2025 Earnings Call August 28, 2025 9:00 AM ETCompany ParticipantsAllison Mead Talbot - Senior VP of Communications...
PureTech Health plc reports 1H results
Earnings Scheduled For August 28, 2025
Companies Reporting Before The Bell • Li Auto (NASDAQ: LI) is expected to report earnings for its second quarter. • PureTech Health (NASDAQ: PRTC) is estimated to report earnings for its first quart...
PureTech Health plc – Half-Year Report
BOSTON--(BUSINESS WIRE)--PureTech today announces its half-yearly results for the six months ended June 30, 2025.
PureTech Showcases Differentiated Development Strategy, Including New Patient Preference Insights, and Spotlights Phase 2b Data Positioning Deupirfenidone as a Potential New Standard of Care in IPF
BOSTON--(BUSINESS WIRE)--PureTech Demonstrates Strategic and Scientific Leadership in Idiopathic Pulmonary Fibrosis at 2025 IPF Summit.
PureTech Health: Notice of Half-Yearly Results
BOSTON--(BUSINESS WIRE)--PureTech Health: Notice of Half-Yearly Results.
PureTech Founded Entity Vedanta Biosciences Announces Phase 2 Study of VE202 in Ulcerative Colitis Did Not Meet Primary Endpoint
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Vedanta Biosciences Announces Phase 2 Study of VE202 in Ulcerative Colitis Did Not Meet Primary Endpoint.
PureTech Announces the Launch of Celea Therapeutics With a Mission to Transform the Treatment of Respiratory Diseases
BOSTON--(BUSINESS WIRE)--PureTech Announces the Launch of Celea Therapeutics with a Mission to Transform the Treatment of Respiratory Diseases.
PureTech Health announces CEO transition
PureTech Announces Leadership Transition
BOSTON--(BUSINESS WIRE)--PureTech Announces Leadership Transition.
PureTech Announces Board Change
BOSTON--(BUSINESS WIRE)--PureTech Announces Board Change.
Why This Biotech Stock Just Doubled In A Single Day
Vor Biopharma Inc. (NASDAQ: VOR) saw its stock climb Thursday following a strategic licensing agreement and a major capital raise to support its push into autoimmune therapies . The developments mark...
PureTech Health: Results of Annual General Meeting
BOSTON--(BUSINESS WIRE)--PureTech Health: Results of Annual General Meeting.
PureTech to Present at the Jefferies Global Healthcare Conference
BOSTON--(BUSINESS WIRE)--PureTech to Present at the Jefferies Global Healthcare Conference.
PureTech Announces Publication of New Research Highlighting Untold Experiences of People Living with Idiopathic Pulmonary Fibrosis (IPF)
BOSTON--(BUSINESS WIRE)--PureTech Announces Publication of New Research Highlighting Untold Experiences of People Living with Idiopathic Pulmonary Fibrosis (IPF).
PureTech Health PLC (PTCHF) (FY 2024) Earnings Call Highlights: Strong Financial Execution and ...
PureTech Health PLC (PTCHF) (FY 2024) Earnings Call Highlights: Strong Financial Execution and Strategic Milestones
PureTech to Present Results from Phase 2b ELEVATE IPF Trial of Deupirfenidone (LYT-100) at the American Thoracic Society International Conference
BOSTON--(BUSINESS WIRE)--PureTech to Present Results from Phase 2b ELEVATE IPF Trial of Deupirfenidone (LYT-100) at the American Thoracic Society International Conference.
PureTech Health plc 2024 Q4 - Results - Earnings Call Presentation
PureTech Health plc (PRTC) Q4 2024 Earnings Call Transcript
PureTech Health plc (NASDAQ:PRTC) Q4 2024 Earnings Call April 30, 2025 9:00 AM ET Company Participants Allison Mead Talbot - Senior Vice President, Communications Bharatt Chowrira - Chief Executive O...
PureTech Announces Annual Results for Year Ended December 31, 2024
BOSTON--(BUSINESS WIRE)--PureTech Announces Annual Results for Year Ended December 31, 2024.